(BEAM) Beam Therapeutics - Ratings and Ratios

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company specializing in the development of precision genetic medicines. The firm focuses on treating severe genetic diseases through its proprietary base editing technology, which enables precise DNA edits without inducing double-strand breaks. Its pipeline includes BEAM-101 for sickle cell disease, BEAM-302 for alpha-1 antitrypsin deficiency, and BEAM-301 for glycogen storage disease 1a. The company is also advancing BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for sickle cell disease and beta-thalassemia. Additionally, Beam Therapeutics is exploring ex vivo CAR-T therapies, including BEAM-201.

Beam Therapeutics has established multiple research collaborations, including partnerships with Pfizer Inc. to develop in vivo base editing programs for rare genetic diseases, Apellis Pharmaceuticals to target specific genes in the complement system, and Verve Therapeutics for cardiovascular disease treatments. The company also collaborates with Sana Biotechnology to leverage CRISPR Cas12b for cell therapy programs and with Orbital Therapeutics to design RNA for various therapeutic applications. Founded in 2017 and headquartered in Cambridge, Massachusetts, Beam Therapeutics is a leading player in the genetic medicine space.

Beam Therapeutics Inc. operates under the ticker symbol BEAM on the NASDAQ exchange, classified as a common stock in the Biotechnology sub-industry. The company’s market capitalization is approximately $1.998 billion USD, with a price-to-book ratio of 2.72 and a price-to-sales ratio of 31.46. The return on equity stands at -51.36%, reflecting the company’s focus on research and development over profitability. For more information, visit their website at https://beamtx.com.